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Abstract 
Human embryonic stem cell-derived cardiomyocytes (hESC-CMs) provide a promising 
source for cell therapy and drug screening. Several high-yield protocols exist for hESC-CM 
production; however, methods to significantly advance hESC-CM maturation are still lacking. 
Building on our previous experience with mouse ESC-CMs, we investigated the effects of 3-
dimensional (3D) tissue-engineered culture environment and cardiomyocyte purity on 
structural and functional maturation of hESC-CMs. 2D monolayer and 3D fibrin-based 
cardiac patch cultures were generated using dissociated cells from differentiated Hes2 
embryoid bodies containing varying percentage (48-90%) of CD172a (SIRPA)-positive 
cardiomyocytes. hESC-CMs within the patch were aligned uniformly by locally controlling 
the direction of passive tension. Compared to hESC-CMs in age (2 weeks) and purity (48-
65%) matched 2D monolayers, hESC-CMs in 3D patches exhibited significantly higher 
conduction velocities (CVs), longer sarcomeres (2.09±0.02 vs. 1.77±0.01 µm), and enhanced 
expression of genes involved in cardiac contractile function, including cTnT, αMHC, CASQ2 
and SERCA2. The CVs in cardiac patches increased with cardiomyocyte purity, reaching 
25.1 cm/s in patches constructed with 90% hESC-CMs. Maximum contractile force 
amplitudes and active stresses of cardiac patches averaged to 3.0±1.1 mN and 11.8±4.5 
mN/mm2, respectively. Moreover, contractile force per input cardiomyocyte averaged to 
5.7±1.1 nN/cell and showed a negative correlation with hESC-CM purity. Finally, patches 
exhibited significant positive inotropy with isoproterenol administration (1.7±0.3-fold force 
increase, EC50 = 95.1 nM). These results demonstrate highly advanced levels of hESC-CM 
maturation after 2 weeks of 3D cardiac patch culture and carry important implications for 
future drug development and cell therapy studies. 
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Introduction 
Since the discovery of human embryonic (hESCs) and induced pluripotent stem cells 
(hiPSCs), significant efforts have been made to enable efficient production of human 
cardiomyocytes (CMs) [1]. Of particular importance to clinical translation are the recently 
developed techniques for high-yield cardiac differentiation that do not require the use of 
genetic modifications [2-7]. Furthermore, new purification protocols based on cell-surface 
markers (SIRPA, VCAM1) [8, 9], mitochondrial fluorescence dyes (TMRM)[10], or distinct 
metabolic flows in CMs and non-CMs [11] have enabled generation of virtually pure (>95%) 
cardiomyocyte populations. Despite these advances, human pluripotent stem cell-derived 
cardiomyocytes (hPSC-CMs) retain a relatively immature phenotype and, unlike their adult 
counterparts, exhibit relatively small size, reduced electrical excitability [1, 12], impaired 
excitation-contraction coupling [13-17] and incomplete adrenergic sensitivity [18, 19]. The 
lack of robust methodologies to promote functional maturation of human cardiomyocytes is 
currently one of the critical obstacles to the successful development of predictive drug and 
toxicology screens as well as safe and efficient cardiac therapies. 
In general, functional maturity of cardiomyocytes at the tissue level is evidenced by 
their ability to support fast action potential conduction and generate high contractile stresses. 
Previously, genetically purified (>95%) hiPSC-CMs were shown to support relatively fast 
(~21 cm/s) electrical conduction in 2D cultures (monolayers) [20], although similar velocities 
have not been achieved in a handful of studies that assessed the functional output of 
engineered 3D human heart tissues [19, 21-23]. In the best reported case [21], tissues made of 
genetically purified hESC-CMs exhibited contractile stresses (4.4 mN/mm2) and conduction 
velocities (<4.9 cm/s), an order of magnitude lower than adult human myocardium (20-45 
mN/mm2 and 40-50 cm/s)![24, 25]. As such, it remains unknown whether hPSC-CMs can be 
matured in vitro to attain both high CVs and contractile stresses, as well as how 
cardiomyocyte purity and 3D culture affect functional output and maturation of human 
engineered cardiac tissues. 
To address these questions, we generated 2D and 3D cultures of human ESC-CMs 
based on our recent experience engineering functional cardiac tissues using mouse ESC-CMs 
[26]. The goal of 3D culture model was to assess the electrical and mechanical maturation of 
hESC-CM. Specifically, quantification of electrical impulse propagation and mechanical 
force generation was used to assess the overall tissue function, with subsequent 
immunofluorescence and genetic profiling to assess the structural and molecular properties of 
the hESC-CMs. Finally, levels of advanced maturity were assessed using beta-adrenergic 
stimulation of the engineered tissues. 
  
Materials and Methods 
Cardiac differentiation of hESCs 
Human ES cells (HES-2 line) were trypsin-adapted and differentiated to a cardiovascular 
lineage based on previously described methods (Fig. S1A) [9]. Briefly, two days prior to 
differentiation (d-2), hESCs were plated on Matrigel (BD Biosciences) coated plates for 
feeder depletion. EBs were formed by aggregating trypsinized ES cell clusters in StemPro-34 
media containing BMP4 (0.5 ng/ml) in low-attachment plates overnight (d-1) in humidified 
incubator and cultured under hypoxic conditions (5% O2, 5% CO2, 37°C) until day 11. On 
day 0 (start of differentiation), EBs were harvested and resuspended in Induction Medium 
(StemPro-34, bFGF (5 ng/ml), activin A (6 ng/ml) and BMP4 (10 ng/ml)) and cultured for 3 
days. On day 4, EBs were harvested and resuspended in StemPro-34 supplemented with 
VEGF (10 ng/ml) and Wnt-C59 (2 µM, Cellagen Technology). Medium was exchanged on 
day 6 with StemPro-34 supplemented with VEGF (10 ng/ml). On day 8, 11, and 15, medium 
was exchanged with StemPro-34 supplemented with only VEGF (10 ng/ml) and bFGF (5 
ng/ml). On day 11, EBs were moved from hypoxic (5% O2, 5% CO2, 37°C) to ambient 
oxygen condition (5% CO2, ambient air, 37°C). From day 18 on, medium was replaced with 
fresh 2% FBS/DMEM every 3 days. hESC-CMs were used on days 22-30 of differentiation. 
All StemPro-34 media included L-glutamine (2 mM), transferrin (150 µg/ml, Roche), 
ascorbic acid (50 µg/ml), and monothioglycerol (0.45 mM). Medium supplements were 
purchased from Life Technologies Corporations, unless otherwise stated. Chemicals were 
obtained from Sigma Aldrich and all growth factors were obtained from R&D Systems.  
 
 
Dissociation of differentiated cell clusters 
Beating cell clusters were dissociated using 0.2% collagenase type I (Sigma C-0130) in 20% 
FBS/DMEM (Gibco) at 37°C for 1 hour, followed by 0.25% trypsin/EDTA (Cellgro) with 
gentle shaking in a 37°C water bath for 5-7 minutes.  Single-cell suspension was achieved by 
triturating with equal volume of 50% FBS/DMEM + 20µg/ml DNase (Calbiochem). 
 
Purification of hESC-CMs 
For monolayer and patch cultures, the fraction of cardiomyocytes in dissociated cells was 
enriched by magnetic-activated cell sorting (MACS). Briefly, dissociated cells (5x106 
cells/ml) were stained with PE-Cy7 conjugated anti-SIRPA-IgG antibody (clone SE5A5; 
BioLegend; 1:500). Labeled cells were loaded with anti-PE-Cy7 MicroBeads, and the 
cell/bead mix was passed through MS Columns on a MiniMACS™ separator (Miltenyi 
Biotec). Small fractions of immunolabeled cells (MSC sorted and unsorted) were then 
analyzed using the flow cytometer FACSAria II with FACSDiva software, version 6.0 (BD 
Biosciences). Cardiac specificity of SIRPA was confirmed by FACS analysis (Fig. S1B-D) 
for cardiac troponin T (cTnT) which showed that  >92% of SIRPA+ cells in MACS sorted 
and unsorted populations consisted of cTnT+ cardiomyocytes. Based on this analysis, MACS 
sorted and unsorted cells were mixed in different ratios to obtain 48-90% pure hESC-CM 
populations used for patch and monolayer production.  
 
Cardiac patch fabrication and culture 
To generate aligned 3D human cardiac tissue patches, 7x7mm2 polydimethylsiloxane (PDMS, 
Dow Corning) molds with staggered hexagonal posts (1.2 mm long) were microfabricated as 
previously described [27].  Hydrogel solution (24 µL fibrinogen (10 mg/mL), 12 µL Matrigel, 
24 µL 2x cardiac media)) was mixed with 1x106 cells in 59 µL cardiac media to obtain a total 
of 120 µl of cell/gel solution. Following addition of thrombin (0.92 µL), cell/gel solution was 
added to PDMS molds containing a Velcro frame and left at 37ºC for 1hr to polymerize. 
Resulting cardiac patches were cultured with rocking in cardiac medium (5% FBS/DMEM 
with 1mM sodium pyruvate (Gibco), 2mM Glutamine (Gibco), 0.1mM non-essential amino 
acids (Gibco), 50 µg/ml Ascorbic Acid (Sigma), and 0.45mM monothioglycerol (Sigma)) for 
4-14 days. Culture media was supplemented daily with 1mg/mL aminocaproic acid (Sigma) 
to prevent fibrin degradation. 10µM BrdU (Sigma) was added on day 0 of patch culture to 
inhibit proliferation of non-myocytes and preserve initial purity of hESC-CMs. BrdU was 
removed after 24 h of culture, and media was changed every 2 days thereafter. 
 
Assessment of electrical propagation 
Optical mapping of transmembrane potentials was performed after 2 weeks of culture using 
our established methods [26, 28, 29]. Two-second episodes of electrical activity induced by 
stimulation with point electrode were recorded in macroscopic (whole tissue) or microscopic 
(4x objective on a Nikon microscope) mode using a 504-channel photodiode array (RedShirt 
Imaging) or a fast EMCCD camera (iXonEM+, Andor). Data analysis was performed using 
custom MATLAB software [28]. 
 
 
Assessment of contractile force generation 
Force generating capacity of cardiac tissue patches was assessed in 2-week old patches 
loaded into a custom-made isometric force measurement setup containing a sensitive optical 
force transducer and a computer-controlled linear actuator (Thorlabs), as previously 
described [26, 29, 30]. Inotropic responsiveness of the tissue patches was tested by 
measurement of contractile force generation in the presence of 10-10, 10-9, 10-8, 10-7, 10-6 and 
10-5 M β-adrenergic agonist isoproterenol in 0.9mM Ca2+ Tyrode’s solution during 1Hz 
electrical stimulation at 10% stretch. 
 
Statistical analysis 
Experimental data reported as mean ± SEM was compared by one-way ANOVA and 
unpaired t-test. Wilcoxon Rank-Sum test (median, Z-score, p-value) was used for non-normal 
distributions. A bivariate linear regression analysis was performed to determine significance 
of linear fits. A p-value of 0.05 was considered significant. 
 
Additional details and assessment methodologies are provided in Supplemental Materials. 
 
Results  
Electrophysiological properties of hESC-CMs 
Action potential properties of dissociated unpurified hESC-CMs were assessed using patch-
clamp recordings. After 20-30 days of differentiation cardiomyocytes exhibited a 
predominantly ventricular action potential (AP) phenotype with hyperpolarized resting 
membrane potentials (-70.9±0.5 mV) and relatively fast maximum upstroke velocities 
(38.1±1.5 V/s) (Fig. S2A). Studied hESC-CMs exhibited expected dose-dependent responses 
to HERG K+ channel blocker E-4031, L-type Ca2+ channel blocker nifedipine, and ATP-
sensitive K+ channel blocker terfenadine (Fig. S2B). Specifically, the application of E-4031 
and terfenadine caused a significant increase in action potential duration at 90% 
repolarization (APD90), while nifedipine caused a large decrease in APD90 (Fig. S2C), 
showing physiological responses to inhibition of K+ and Ca2+ channels. 
 
Structural phenotype of human cardiac tissue patches and monolayers 
Differentiated cell populations with varying hESC-CM purity (48-90%) were cultured in 20 
mm-diameter confluent monolayers and 7x7mm2 porous 3D cardiac tissue patches (Fig. 1A-
B, Movie 1). Elliptical pores in the patches facilitated nutrient transport and enabled the 
formation of uniformly dense and aligned cardiac tissue [26] (Fig. 1C and S3). 
Immunostaining for cardiac markers revealed aligned cardiomyocytes that exhibited cross-
striated patterns of troponin T (cTnT, Fig. 1D), myosin heavy chain (MHC, Fig. 1E) and α-
actinin (SAA, Fig. 2A), indicative of well-developed sarcomeric structures. Additionally, N-
cadherin and connexin-43 (Cx43) immunostaining demonstrated presence of intercellular gap 
and adherens junctions, respectively, suggestive of functional electromechanical coupling 
between cardiomyocytes (Fig. 1F and 2A). Confocal analysis of non-cardiac cell markers 
revealed the presence of SM22α+ smooth muscle cells (Fig. 1F) that resided primarily at the 
patch surface along with vWF-/Vim+ fibroblasts (Fig. S4), while vWF+/Vim+ endothelial cells 
(Fig. 1F) occupied the patch interior (Fig. S4). Similar to 3D patches, 2D monolayer cultures 
also contained cross-striated hESC-CMs (Fig. 2B) interspersed with both fibroblasts and 
vascular cells (data not shown). Importantly, hESC-CMs in 3D tissue patches exhibited 
significantly longer sarcomeres then in 2D monolayers (2.09±0.02 vs. 1.77±0.01 µm, Fig. 
2C,D), reaching optimal sarcomere length measured in adult human cardiomyocytes [31].   
 
Time course of cardiac gene expression 
Using qRT-PCR, we assessed expression of pluripotency and cardiac-specific genes (for the 
list of primers see Table S1) in undifferentiated hESCs, differentiated hESCs, and cardiac 
patches and monolayers at different times of culture. As expected, OCT4 and NANOG 
expression decreased significantly during hESC differentiation and virtually disappeared in 
patches (Fig. 3A,B) and monolayers (not shown). Early cardiac markers ISL1 and GATA4 
increased with cardiac differentiation, with ISL1 decreasing during subsequent patch culture 
(Fig. 3C). Consistent with human ventricular development [32, 33], gene expression levels of 
βMHC and MLC2v increased and αMHC decreased during patch culture, yielding a 
significant increase in βMHC/αMHC and MLC2v/MLC2a expression ratios (Fig. 3D-F). 
Furthermore, expression of genes that determine AP shape and propagation (Fig. 3G) either 
increased with tissue patch culture (Cx43, Nav1.5, Kv4.3) or remained unchanged (Kir2.1, 
Cav1.2). Interestingly, genes crucial for excitation-contraction (E-C) coupling (CASQ2, 
SERCA2) were significantly upregulated during 2-week patch culture (Fig. 3H,I), showing a 
170-fold increase in calsequestrin expression that was previously shown to be lacking in 2D 
cultured hESC-CMs [13, 14]. Compared to 2D monolayers, hESC-CMs in 3D patches had 
significantly upregulated genes required for cardiac E-C coupling (Fig. 3H,I) and contractile 
function (cTnT, αMHC, Fig. S5). In contrast, culture environment (2D vs. 3D) had no major 
influence on genes important for cardiac electrical function (Fig. 3G). 
 
Action potential conduction in cardiac patches and monolayers 
Optical mapping of transmembrane potentials (Fig. 4A) revealed macroscopically continuous 
action potential propagation in both tissue patches (Fig. 4B, Movie 2) and monolayers (Fig. 
4C, Movie 3). Interestingly, conduction velocity (CV) in cardiac patches increased linearly 
with hESC-CM purity, reaching 25.1 cm/s in patches made of 90% cardiomyocytes (Fig. 4D). 
Compared to age- and purity- (48-65%) matched 2D monolayers, 3D patches exhibited 
significantly higher CVs (9.76±1.0 vs. 5.17±0.7 cm/s, Fig. 4D), but not significantly different 
action potential durations (APD, 338±30 vs. 278±20 ms, Fig. 4E) or maximum capture rates 
(MCR, 2.6±0.2 vs. 2.6±0.1 Hz, Fig. 4F). In contrast to CVs, neither APDs nor MCRs in 
patches or monolayers showed significant correlation with hESC-CM purity. Both CV and 
APD in patches decreased with increased pacing frequency (electrical restitution), while 
monolayers showed only significant APD restitution (Fig. S6A,B). Thus, 3D cardiac patches 
appeared to form a more functional electrical syncytium than 2D monolayers. 
 
Contractile properties of cardiac tissue patches 
Assessment of isometric force generation revealed that electrically stimulated cardiac tissue 
patches generated active forces (twitch contractions) that increased with applied stretch in a 
Frank-Starling-like fashion (Fig. 5A,B). Maximum active (contractile) forces averaged to 
3.0±1.1 mN and showed no significant correlation with hESC-CM purity (Fig. 5C). Based on 
measurements of the patch width (7 mm), thickness (73.6±6.6 µm, Fig. S3), percent pore area 
in the patch (porosity, 39.5±4.9%), and distribution of cell alignments [30], we estimated the 
average contractile stress in our cardiac patches to be 11.8±4.5 mN/mm2. Since methods to 
calculate contractile stress amplitudes may vary among different research groups, we also 
calculated a functional parameter that can serve to quantify the “efficiency of a cardiac tissue 
engineering system” by dividing the contractile force amplitude in each cardiac patch (system 
output) with the number of cardiomyocytes used to make the patch (system input). The 
calculated contractile-force-per-input-cardiomyocyte in our patches averaged to 5.7±1.0 
nN/cell and decreased with increase in hESC-CM purity (Fig. 5D). Similar to active forces, 
passive tension in patches increased with applied stretch (Fig. 5B), but significantly 
decreased with hESC-CM purity (Fig. S7A), yielding a linear increase in the active:passive 
force ratio for patches with higher hESC-CM purity (Fig. S7B). Along with being 
mechanically softer, patches made with higher percent cardiomyocytes also displayed shorter 
twitch rise times (Fig. S7C,D).  
Finally, we tested the sensitivity of engineered cardiac tissue patches to beta-
adrenergic stimulation. Increasing doses of β-adrenergic agonist isoproterenol caused an 
expected increase in spontaneous contraction frequency (data not shown) as well as a 
sigmoidal increase in twitch amplitude (up to ~1.7±0.3 fold with EC50 of 95.1 nM, Fig. 6A,B). 
Furthermore, increasing isoproterenol concentrations yielded significant shortening of twitch 
rise time (Fig. 6C) indicative of accelerated force generation. Together with the results of 
structural, gene expression, and electrophysiological analyses, the high contractile stresses 
and inotropic responsiveness to adrenergic stimulation collectively demonstrated advanced 
functional maturation of hESC-CMs in the cardiac tissue patches. 
  
Discussion  
In this study, we generated relatively large, aligned, and highly functional cardiac 
tissue patches using human embryonic stem cell-derived cardiomyocytes. Our results 
demonstrate that after only two weeks of culture, the optimized 3D environment of a cardiac 
tissue patch can yield advanced levels of structural and functional maturation of hESC-CMs, 
as evidenced by their mature sarcomeric organization, enhanced cardiac gene expression 
profiles, and robust functional output. Specifically, we show that: 1) aligned human heart 
tissues can be engineered with a sheet-like (rather than cable) geometry and exhibit both high 
CVs (up to 25.1 cm/s) and contractile forces and stresses (3.0 mN and 11.8 mN/mm2), 2) 
initial hESC-CM purity uniquely determines the electromechanical properties of the 
engineered myocardium, and 3) hESC-CM maturation in optimized 3D patch environment is 
enhanced relative to that in standard 2D cultures. Additionally, engineered cardiac tissue 
patches demonstrated significant adrenergic responsiveness, confirming the advanced 
maturation state of hESC-CMs. These results build on our previous studies that established 
the optimal in vitro conditions for the formation of mouse ESC-derived myocardium and 
demonstrated a requisite role of non-cardiomyocytes in this process [26]. Similarly, in this 
study, the formation and/or maturation of functional human myocardium may have been 
supported by the presence of endothelial, smooth muscle, and fibroblastic cells in the patch. 
These cells have been differentiated together with cardiomyocytes from the same hESC 
source, thus avoiding the need for supplementation with exogenous non-cardiac cells, as 
employed in previous studies [21, 23, 34].  
Methods for engineering contractile human cardiac tissues from pluripotent stem cell-
derived cardiomyocytes have involved the use of scaffold-free cell sheets [35], porous 
polymer scaffolds [34], and different hydrogels, including collagen [21-23, 36], fibrin [19], 
and cardiac ECM-derived hydrogels [37]. Among these studies, only four [19, 21-23] have 
assessed tissue contractile function and only one [21] has also assessed electrical function of 
the engineered myocardium. Compared to these reports, cardiac tissue patches generated in 
our study exhibit 2.2-180-fold and 2.6-150-fold higher contractile force and stress generation, 
respectively (see Table S2 for all previous reports on functional assessment of primary and 
stem cell-derived engineered cardiac tissues). Due to a lack of standardized methods to 
calculate contractile stress amplitude (e.g. in geometrically complex tissues), we also 
introduced a unifying metric for quantifying the efficiency of a cardiac tissue engineering 
approach by dividing the maximum contractile force of a cardiac construct by the number of 
cardiomyocytes used for its production. Using this metric, we further showed 4-700-fold 
higher efficiency of our cardiac tissue approach (average force-per-CM ratio of 5.7 nN/cell) 
than previously achieved (Fig. 5D, Table S2). In addition, the maximum velocities of action 
potential propagation achieved in this study (at 80-90% hESC-CM purity) represent a 5-fold 
increase compared to previous reports in human engineered tissues [21] (Table S2). Overall, 
cardiac tissue patches exhibited high contractile stresses and conduction velocities that are 
only 2-3 times lower than those reported for adult human myocardium (Table S2). 
We also explored the effects of the initial hESC-CM purity on electromechanical 
properties of the engineered cardiac tissues. We found that higher CM purities produced 
faster CVs but had no significant effect on contractile force production (at least for 48-90% 
purity), thus yielding a decrease in force-per-input-cardiomyocyte ratio. While higher CM 
purity (i.e. less non-myocytes) would expectedly facilitate cardiomyocyte contacts and 
increase CV, lack of force augmentation may result from a limit on the CM survival in a 
given patch volume. Thus, the use of hydrogels seeded at low density with high purity of 
hESC-CMs may be the most efficient strategy to maximize CM survival and 
electromechanical output of 3D engineered myocardium. This strategy could be used for the 
optimal design of high-throughput screening platforms that employ 3D functional engineered 
cardiac tissues while utilizing minimum numbers of human CMs. 
Furthermore, we demonstrated that relative to standard 2D culture, 3D patch 
environment significantly enhanced hESC-CM maturation. Specifically, on a structural level, 
3D culture promoted an increase in sarcomere length to values comparable to those of adult 
human cardiomyocytes. Previously, sarcomere lengthening in hiPSC- and hESC-CMs was 
induced through mechanical stretch [21]; however, achieved sarcomere lengths remained at 
sub-adult values [31]. Interestingly, the 3D patch culture also enhanced expression of genes 
determining cardiac contractile function and Ca2+ handling (cTnT, αMHC, SERCA2, 
CASQ2) but not electrical function (Cx43, Nav1.5, Kir2.1, Cav1.2). Combined with studies 
showing high CVs in relatively pure hiPSC-CM monolayers [20], our results suggest that 2D 
monolayers and 3D sheet-like patches may be of similar utility for studies of cardiac impulse 
propagation and related arrhythmogenesis. On the other hand, the advanced structural and 
contractile characteristics of hESC-CMs in 3D cardiac patches would render them preferred 
over 2D monolayers for physiological and pharmacological studies of cardiac contractile 
function and excitation-contraction coupling.  
In support of this notion, cardiac patches were found to exhibit a robust inotropic 
response (i.e. an increased amplitude and faster kinetics of force generation) to a β-adrenergic 
agonist, isoproterenol. The inotropic effects of isoproterenol are characteristic of the adult 
human myocardium and require a functional sarcoplasmic reticulum, capable of releasing 
larger amounts of Ca2+ more quickly upon adrenergic stimulation [38, 39]. While this effect 
has been previously observed in some hESC-CM preparations [21, 40] but not others [18, 19], 
the relative sensitivity of the inotropic response to isoproterenol was not assessed. Our 
measured EC50 of 95.1 nM falls in the 30-160 nM range reported for adult human ventricular 
tissue [41, 42], suggesting a near-physiological sensitivity to adrenergic stimulation.  
 
Conclusion 
We have established methodologies for successful engineering of a highly functional human 
cardiac tissue patch starting from hESC-derived cardiomyocytes. The structural and 
functional properties of these 3D tissue patches, along with the resultant maturation state of 
hESC-CMs, surpass all previous reports for engineered human myocardium and currently 
provide the closest in vitro approximation of native human heart tissue. Overall, the use of 
non-genetic methods to purify human pluripotent stem cell-derived CMs, the derivation of 
vascular cells along with cardiomyocytes, aligned tissue structure, and robust functional 
output of the obtained cardiac patches all warrant the future use of this tissue-engineering 
platform for predictive drug and toxicology testing and development of effective cell-based 
cardiac therapies. 
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Figure legends 
Figure 1. Structural properties of human cardiac tissue patches. A) Representative 2-
week old cardiac tissue patch anchored within a Velcro frame. B-C) Staggered elliptical pores 
within the patch (B) are surrounded by densely packed and aligned cells (C). D) hESC-CMs 
in 2-week old cardiac tissue patches are aligned and show cross-striated patterning of cardiac 
Troponin T (cTnT). Fibroblasts positive for vimentin (Vim) are interspersed among hESC-
CMs. E) hESC-CMs also exhibit cross-striated pattern of myosin heavy chain (MHC) and 
sarcomeric α-actinin (SAA). F) Cardiac patches show evidence of mechanical coupling (N-
cadherin) between hESC-CMs as well as presence of smooth muscle cells (SM22α). Data 
shown for patches made with 70% hESC-CMs. 
 
Figure 2. hESC-CMs in 3D patches exhibit longer sarcomeres than in 2D monolayers. 
A) Representative immunostainings of hESC-CMs in 2-week old tissue patch coupled by 
connexin-43 gap junctions. B) hESC-CMs in 2-week old monolayers. C) Histogram 
distribution of sarcomere lengths in 2-week old patches and monolayers made with 48-65% 
hESC-CMs. Note increased sarcomere length in patches vs. monolayers. D) Median and 
quartile sarcomere lengths in monolayers (n=58 hESC-CMs) and patches (n=106 hESC-
CMs). *p<0.0001. 
 
Figure 3. Quantitative gene expression during patch and monolayer culture. A-C) qPCR 
readout of pluripotency (OCT4 and NANOG) and cardiac progenitor (ISL1 and GATA4) 
genes in undifferentiated hESCs (ES), beating cell clusters (PM0), and cardiac patches at 4 
days (P4D), 1 week (P1W), and 2 weeks (P2W) of culture. D-F) qPCR readout of contractile 
function genes: MHC, myosin heavy chain; cTnT, cardiac Troponin T; MLC2v/a, Myosin 
light chain 2 ventricular/atrial. G-I) qPCR readout of electrical function (Nav1.5, fast Na+ 
channel; Kir2.1, inward rectifier K+ channel; Kv4.3, transient outward K+ channel; Cav1.2, 
L-type Ca2+ channel) and excitation-contraction (SERCA2, SR Ca2+-ATPase; CASQ2, 
calsequestrin) genes in patches and monolayers of the same age (M1W and M2W, 1 and 2 
week monolayer) and hESC-CM purity (60-65%). All data except F are shown relative to 
PM0 group. n = 2–4 biological x 3 technical replicates. p<0.05 from: *, PM0; **, all other 
groups; †, ES; #, another group. 
 
Figure 4. Action potential propagation in cardiac patches and monolayers. A) 
Representative optically mapped action potential traces in a 2-week old cardiac patch at 
various pacing rates. B,C)  Representative isochrone maps during 1 Hz point stimulation of a 
2-week old cardiac patch (B) and monolayer (C). D-F) Conduction velocity (D), action 
potential duration (E), and maximum capture rate (F) during point stimulation of cardiac 
patches and monolayers as a function of hESC-CM purity. †p<0.05 between patches and 
monolayers (48% < hESC-CM purity < 65%.) 
 
Figure 5. Contractile properties of cardiac tissue patches. A) Representative active 
(contractile) force traces during progressive stretch of an electrically stimulated (1Hz) 2-week 
cardiac patch. B) Corresponding active and passive force-length relationships in cardiac 
patches made with 57%-65% hESC-CMs (n=5). C) Maximum contractile force (at 1 Hz 
stimulation) in 2-week patches as a function of hESC-CM purity. D) Contractile force per 
input hESC-CM as a function of cardiomyocyte purity; p<0.03 for linear trend.  
 
Figure 6. Inotropic response of cardiac tissue patches to beta-adrenergic stimulation. A) 
Representative active force traces in a tissue patch made with 55% hESC-CMs during 
application of increasing doses of isoproterenol (measured at 10% stretch, 1 Hz stimulation, 
and 0.9 mM extracellular [Ca2+]). B-C) Contractile force amplitude (B) and twitch kinetics 
(C) as a function of isoproterenol concentration (n=4). 
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pacing rates. B,C)  Representative isochrone maps during 1 Hz point stimulation of a 2-week 
old cardiac patch (B) and monolayer (C). D-F) Conduction velocity (D), action potential 
duration (E), and maximum capture rate (F) during point stimulation of cardiac patches and 
monolayers as a function of hESC-CM purity. †p<0.05 between patches and monolayers (48% 
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!!
SUPPLEMENTAL MATERIAL 
 
Detailed Methods 
 
Maintenance of human embryonic stem cells 
Human ES cells, trypsin-adapted HES-2, were maintained on MEF feeders in hESC medium 
(DMEM/F12 medium supplemented with KnockOut serum replacement (20% vol/vol, Life 
Technologies Corporations), L-glutamine (1mM), nonessential amino acids (0.1 mM), β-
mercaptoethanol (0.1 mM), and human basic fibroblast growth factor, bFGF (20 ng/ml)).    
 
Intracellular electrophysiological measurements  
The in vitro effects of E-4031, terfenadine and nifedipine on action potentials recorded from hESC-CMs 
were measured using perforated patch whole-cell recordings with four nominal concentrations of each 
drug (E-4031 0.003, 0.01, 0.03, 0.1 µM; terfenadine 0.003, 0.01, 0.03, 0.1 µM; nifedipine 0.03, 0.1, 0.3, 
1 µM) in at least 4-7 cardiomyocytes. Myocytes were paced continuously (stimulation rate of 1 Hz) until 
a stable baseline was obtained. Only cells with resting potentials more negative than –60 mV were used. 
Drugs were applied until steady state was achieved (5-10 min). In several instances, the application was 
repeated at cumulatively increased drug concentrations. All experiments were performed at 
physiological temperature (35±2oC). Pipette solution contained in mM: 130 KCl, 5 MgCl2, 5 EGTA, 10 
HEPES, pH adjusted to 7.2 with KOH and ~240 µg/mL amphotericin B to permeabilize the cell 
membrane. Bath solution contained in mM: 137 NaCl, 4 KCl, 1.8 CaCl2, 1 MgCl2, 10 HEPES, 10 
glucose, pH adjusted to 7.4 with NaOH. After obtaining a seal (>0.8 GΩ) with a glass patch pipette, 
capacity current transients in voltage clamp mode were monitored for change in access resistance. An 
access resistance of less than 20 MΩ indicated achievement of a perforated patch recording. The patch 
clamp amplifier was switched to current clamp mode and a brief current pulse (up to 3 ms duration) at 
an appropriate level for excitation (approximately twice the voltage threshold for excitation) was used to 
evoke action potentials. 
 
Cardiac monolayer culture 
To compare the effect of 3D vs. 2D culture environment on hESC-CM function and maturation, we also 
prepared 2D cardiac monolayer cultures using cells with a range of hESC-CM purities (48-63%) similar 
to that used for patch fabrication. Cell suspensions were seeded on fibronectin (30 µg/ml) coated 
coverslips at a density of 1.3 x 105 cells/cm2. Similar to cardiac patches, BrdU was added on day 0 of 
culture and removed after 24 h. Media was changed every 2 days thereafter.  
 
Quantitative RT-PCR 
Total RNA was extracted from cells immediately before patch and monolayer culture as well as from 4 
day, 1-week and 2-week old patches and 1- and 2-week old monolayers using Qiashredder and RNeasy 
mini kits (Qiagen) and treated with RNase-free DNase I set according to the manufacturer's instructions. 
Total RNA (about 1-2 µg per 20µl reaction) was reverse transcribed using SuperScript™ II Reverse 
Transcriptase (Invitrogen) primed with random hexamer oligonucleotides (Promega). Quantitative PCR 
was carried out on CFX384 Real-Time PCR system (Bio-Rad) using Sso-Fast EvaGreen Supermix (Bio-
Rad) according to the manufacturer's instructions. Relative expression levels were normalized to 
GAPDH and calculated using the 2−∆Ct method. All primers were purchased from Invitrogen and listed 
in Supplemental Table 1. 
 
!!
Immunofluorescence 
Immunostainings were performed after 2 weeks of culture as previously described1 using the following 
primary antibodies: AlexaFluor 488-conjugated mouse anti-sarcomeric α-actinin (SAA, Invitrogen 
A10468, Sigma A7811, 1:50 dilution), rabbit polyclonal anti-connexin43 (Cx43, Abcam A11370), 
mouse polyclonal anti-vimentin (Vim, Sigma A6630), rabbit polyclonal anti-von Willebrand factor 
(vWF, Abcam ab6994), rabbit polyclonal anti-smooth muscle 22α (SM22α, Abcam ab10135), rabbit 
polyclonal anti-cardiac troponin T (cTnT, Abcam, ab45932), mouse monoclonal anti-heavy chain 
cardiac Myosin (MHC, Abcam, ab15), and mouse monoclonal anti-N-Cadherin (N-Cad, Invitrogen 
180224). Non-conjugated primary antibodies were all used at 1:200 dilutions. Secondary antibodies 
(Invitrogen Alexa Fluor®) were used at 1:400 dilutions. Images were taken on a Zeiss Axio Observer 
inverted confocal microscope and analyzed with Zeiss LSM 510 software.  
 
Optical mapping of action potential propagation 
Optical mapping of transmembrane voltage in monolayers and patches was performed using our 
previously described methods1. Briefly, cells were incubated with a voltage-sensitive dye, di4-ANEPPS 
(15µM, Life Technologies), in standard Tyrode’s solution (in mM: 135 NaCl, 5.4 KCl, 1.8 CaCl, 1 
MgCl, 0.33 NaHPO, 5 HEPES, 5 glucose), and a bipolar platinum point-electrode was used to stimulate 
the edge of the patch or monolayer at varying pacing rates (1-4 Hz). Blebbistatin (5 µM) was added to 
inhibit contractions and eliminate motion artifacts during recordings2. Two-second episodes of electrical 
activity were recorded with 0.83 ms temporal and 750 µm spatial resolution using a 504-channel 
photodiode array (RedShirt Imaging). Velocity of action potential propagation (conduction velocity, 
CV), action potential duration at 80% repolarization (APD), restitution relationships and isochrone maps 
and movies of action potential propagation were derived from acquired signals using our custom 
MATLAB software3.  
 
Measurements of specific contractile force and contractile force-per-input-cardiomyocyte 
To derive force-length relationships, patches were progressively stretched in 2% culture length (140 µm) 
increments to a maximum 20% stretch (1.4 mm elongation) and passive tension was recorded in the 
absence of contractions. In addition, at each patch length, active (contractile) force responses were 
recorded during 1Hz field-electrode stimulation (10ms duration, 8-15V) applied by a Grass stimulator 
(SD9, Grass Technologies). Kinetic properties of contractile forces generation were determined by 
measuring force Rise Time (from 10% to 90% activation) and Decay Time (from 10% to 90% relaxation, 
Fig. S7C). 
 Maximum active stress (specific force) in 2-week old tissue patches was determined using our 
previously described methods4. Briefly, maximum active force that patch hESC-CMs can generate in the 
direction of force measurement, i.e., along long axis of elliptical pores, (Fmax,long), was calculated from 
measured maximum active force and spatial distribution of cell alignments derived from patch F-actin 
images, as previously described4, 5. Patch porosity (P) was determined from phase contrast images of 
tissue patch (e.g. Fig. 1B) as the fraction of the total patch area (7x7mm2) consisting of pores (i.e, total 
void area/total patch area). Average cross-sectional area (Aav) of the patch was calculated by multiplying 
patch width (7mm), average patch thickness measured from confocal stack images (e.g. Fig. S3), and 
patch porosity, P. Active stress (σactive) was then calculated as !!"#$%& = ! !!"#,!"#$!!" .  
To further quantify the efficiency of our cardiac tissue engineering method, we calculated 
"output force per input hES-CM" by dividing Fmax, long, representing the functional output of our cardiac 
tissue-engineered system, by the number of hESC-CMs initially used for patch fabrication, representing 
the input into the system. This same efficiency parameter (in units of nN/cell) was also calculated for 
!!
previously reported tissue engineering methods that measured active force generation in engineered 
human cardiac tissues6-9 and shown in Supplemental Table 2. 
  
Movie legends 
Supplemental Movie 1: Example of beating cardiac tissue patch after 10 days of culture. 
Supplemental Movie 2: Example of optically mapped action potential propagation in a cardiac tissue 
patch demonstrating continuous propagation throughout the hESC-CMs. 
Supplemental Movie 3: Example of optically mapped action potential propagation in a cardiac 
monolayer demonstrating continuous propagation throughout the hESC-CMs. 
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Supplemental Table S1. Primers for quantitative RT-PCR  
Standard 
Gene name 
Gene 
product  Forward  Reverse  size  
GAPDH GAPDH  AATGAAGGGGTCATTGATGG  AAGGTGAAGGTCGGAGTCAA  108  
POU5F1 OCT4  CAAAGCAGAAACCCTCGTGC  TCTCACTCGGTTCTCGATACTG  64  
NANOG NANOG  CCCCAGCCTTTACTCTTCCTA  CCAGGTTGAATTGTTCCAGGTC  97  
GATA4 GATA4  CAGGCGTTGCACAGATAGTG  CCCGACACCCCAATCTC  124  
ISL1 ISL1  AAACAGGAGCTCCAGCAAAA  AGCTACAGGACAGGCCAAGA  157  
MYH6 ɑMHC  ACCAACCTGTCCAAGTTCCG  TTGCTTGGCACCAATGTCAC  123  
MYH7 ßMHC  CACAGCCATGGGAGATTCGG  CAGGCACGAAGACATCCTTCT  128  
MYL2 MLC2v  GGGCGGAGTGTGGAATTCTT  CCCGGCTCTCTTCTTTGCTT  83  
MYL7 MLC2a  CCAACGTGGTTCTTCCAACG  TAGGTCTCCCTCAGGTCTGC  129  
TNNT2 cTNT  ATAGAGCCTGGCCTCCTTCA  CTAGGCCAGCTCCCCATTTC  130  
GJA1 Cx43 TGAGCAGTCTGCCTTTCGTT  CCAGAAGCGCACATGAGAGA  94 
KCNJ2 Kir2.1 TGTCACGGATGAATGCCCAA  CTGCGCCAATGATGAAAGCA  89 
KCND3 Kv4.3  CACTCATCGAGAGCCAGCAT  TCTTGATGGTGGAGGTTCGT  111 
SCN5A Nav1.5  TTCAGGGCTGAAGACCATCG  GCACTTGTGCCTTAGGTTGC  142 
CACNA1C Cav1.2 ACATGCTCTTCACTGGCCTC  CCCACAACAATCAAGGCGTC  115 
ATP2A2 SERCA2  TCAAGCACACTGATCCCGTC  GCTACCACCACTCCCATAGC  112 
CASQ2 CASQ2 GTTGCCCGGGACAATACTGA  CTGTGACATTCACCACCCCA  142 
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Supplemental Table S2. Overview of electrical and mechanical properties of in vitro engineered 3D 
cardiac tissues  
Engineered Cardiac Tissue 
Average CV 
(cm/s) 
Maximum Active 
Force (mN) / 
Active force per 
iCM (nN/cell) 
Maximum 
Active 
 Stress 
(mN/mm2)  
Reference Scaffold Material Cardiogenic Cell Source 
Collagen / Matrigel NRVM - 2.9 4.6 10 
Collagen / Matrigel NRVM - 1.1 - 11 
Collagen ultrafoam NRVM 14.4 - - 12 
Collagen / Matrigel NRVM - 2.5 2.5* 13 
Collagen / Fibrin NRVM - - 0.7a 14 
Fibrin NRVM 23.2 1 1.1-2.1* 15 
Fibrin / Matrigel NRVM - ~0.6 ~2.1* 16 
Fibrin NRVM - 1.3 1.8 17 
Decellularized heart NRVM - 2.2a - 18 
PLGA / Fibronectin NRVM 20.8 - - 19 
Scaffold-free bundle NRVM - 0.2-0.3 2-4 20, 21 
Scaffold-free sheet NRVM 2.8 - - 22 
Collagen / Matrigel NRVM - 0.44 0.42* 23 
Collagen / Matrigel NMVM - 1.1a 1.2a,* 24 
 
Collagen / Matrigel miPSC-CM 2-3 1.4 1a,* 7 
Collagen / Matrigel mESC-CM - 0.48 - 25 
Collagen foam mESC-CM 1.5 - - 26 
Fibrin / Matrigel mESC-CM/CPC 24 2 - 1 
 
Collagen / Matrigel hiPSC-CM - 0.24 / 0.7 - 6 
Collagen / Matrigel hESC-CM < 4.9 1.4 / 1.4b 4.4 7 
Collagen / Matrigel hESC-CM - 0.016* / 0.008 0.08 8 
Fibrin / Matrigel hESC-CM - 0.061 / 0.25 0.12* 9 
Fibrin / Matrigel hESC-CM 21.2 3.0 / 5.7 11.8 Current Study 
 
Native Cardiac Tissue Average CV Maximum Active Stress Reference 
Adult Rat (trabeculae) - 40 27 
Adult Rat (papillary) - 56 28 
Adult Rat (ventricle wall) 44c - 13 
Neonatal Rat (trabeculae) - 9 27 
Neonatal Rat (ventricle wall) 22c - 29 
Adult Human (ventricular strip) - 18.3-22.8 30, 31 
Adult Human (papillary muscle) - 44 28 
Adult Human (ventricle wall) 46c - 32 
*Estimated from cross-sectional area. aEstimated from figures. bBased on estimated 1 million hESC-
CMs in 50-100 cardiac bodies. cExpressed as arithmetic mean of longitudinal and transverse CV. 
Abbreviations: NRVM, neonatal rat ventricular myocyte; NMVM, neonatal mouse ventricular myocyte; 
mESC-CM/CPC, mouse embryonic stem cell-derived cardiomyocyte/cardiovascular progentior; hESC-
CM, human embryonic stem cell-derived cardiomyocyte; hiPSC-CM, human induced pluripotent stem 
cell-derived cardiomyocyte. iCM, input hESC-CM.  
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Supplemental Fig S1. Flow cytometry analysis of hESC-CM purity before and after MACS 
purification using SIRPA antibody. !A) hESC cardiac differentiation protocol. After 3-4 weeks of 
differentiation, cells were purified/analyzed by MACS/FACS and used for patch and monolayer 
culture. B) Negative control PE and FITC isotypes. C) Pre-MACS flow cytometry analysis of SIRPA-
PE (left), cTnT-FITC (middle), and cTnT in SIRPA gate (right). Immunostaining before MACS 
purification shows sparse cTnT+ cells. D) Post-MACS flow cytometry analysis of SIRPA-PE (left), 
cTnT-FITC (middle), and cTnT in SIRPA gate (right). Immunostaining after MACS purification 
shows abundant cTnT+ cells. Note that in unsorted and MACS purified cells, 92-99% of SIRPA+ cells 
are also cTnT+. FSC, Forward-scattered light. cTnT, cardiac troponin T.
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Supplemental Fig S2. Electrophysiological characteristics of hESC-CMs. A) Action potential (AP) 
properties of drug-free (control) hESC-CMs. B) Whole cell current-clamp traces of membrane voltage 
in hESC-CMs in the presence of different concentrations of HERG K+ channel blocker E-4031 (left), L-
type Ca2+ channel blocker nifedipine (middle), and ATP-sensitive K+ channel blocker terfenadine 
(right). C) Quantification of resting membrane potential (RMP), AP upstroke velocity (dV/dtmax), AP 
amplitude (APA), and AP duration at 90% repolarization (APD90) in hESC-CMs treated with either 
E-4031 (0.1uM, n=7), nifedipine (1µM, n=6), or terfenadine (0.1uM, n=4) relative to vehicle control 
(100%); *p<0.05 compared with control. 
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Supplemental Fig S3. Representative confocal image stack demonstrating uniform hESC-CM 
density and alignment throughout the thickness of a 2-week old cardiac tissue patch. Numbers in 
the top left corner denote imaging depth inside the patch. Green, F-actin; blue, DAPI. The patch 
was made of differentiated hESCs containing 70%  hESC-CMs.
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Supplemental Fig S4. Cellular composition of cardiac tissue patches. A) Representative 
immunostaining of a tissue patch made with 65% hESC-CMs showing that endothelial cells double-
positive for von Willebrand factor (vWF) and Vimentin (Vim) were interspersed throughout the patch 
while Vim+/vWF- cells (fibroblasts) were mainly present on the patch surface. B) Sarcomeric alpha 
actinin (SAA)-positive cross-striated cardiomyocytes were aligned throughout the patch (also shown 
in top-right and bottom-right panels in  A). 
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Supplemental Fig S5. Comparative expression of genes important for cardiac 
contractile function in age-matched 2D monolayers and 3D tissue patches. M1W and 
MW2, 1- and 2-week old monolayers; P1W and P2W, 1- and 2-week old tissue patches. 
cTnT, Cardiac troponin T; αMHC, alpha-myosin heavy chain; βMHC, beta-myosin heavy 
chain; MLC2a, myosin light chain-2 atrial; MLC2v, myosin light chain-2 ventricular. Gene 
expression levels in patches are shown normalized to those of age-matched monolayers. #, 
significant difference between patches and monolayers (n = 2-4, with 3 technical 
replicates). Monolayers and patches were made from differentiated hESCs containing 
60-65% hESC-CMs. 
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Supplemental Fig S6. Electrical restitution relationships in 2-week old cardiac tissue patches and 
monolayers. A-B) Dependence of action potential duration (APD) and conduction velocity (CV) on 
pacing frequency. *p<0.05 relative to all other pacing rates. #p<0.05 relative to 1.5 and 2 Hz pacing 
rates; †p<0.05 relative to 1, 1.5, and 2Hz pacing rates. n = 4-5 monolayers, 5 patches between 1-2.5Hz) 
and 2 patches at 3Hz. Monolayers and patches were made from differentiated hESCs containing 48-65% 
hESC-CMs.
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Supplemental Fig S7. Contractile properties of 2-week old cardiac tissue patches. A) Passive 
tension of tissue patches decreases with increased hESC-CM purity of cells used for patch 
production. B) Active:passive force ratio increases linearly with hESC-CM purity. Forces in A-B 
are measured at 10% stretch during 1Hz stimulation. C) Representative isometric twitch force 
traces in cardiac tissue patches (measured at 10% stretch and 1Hz stimulation. D) Rise and Decay 
Times of twitch traces (measured as shown in C) as a function of hESC-CM purity. While both 
Rise and Decay Times appear to decrease with increase in cardiomyocyte purity, only the Rise 
Time shows statistically significant  trend (R2=0.48, p<0.02).
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